[go: up one dir, main page]

WO2024216211A3 - Procédés d'inhibition de la progression d'une tumeur et de la métastase par inhibition de enpp1 - Google Patents

Procédés d'inhibition de la progression d'une tumeur et de la métastase par inhibition de enpp1 Download PDF

Info

Publication number
WO2024216211A3
WO2024216211A3 PCT/US2024/024497 US2024024497W WO2024216211A3 WO 2024216211 A3 WO2024216211 A3 WO 2024216211A3 US 2024024497 W US2024024497 W US 2024024497W WO 2024216211 A3 WO2024216211 A3 WO 2024216211A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
metastasis
enpp1
inhibition
tumor progression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/024497
Other languages
English (en)
Other versions
WO2024216211A2 (fr
Inventor
Songnan WANG
Lingyin Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arc Institute
Leland Stanford Junior University
Original Assignee
Arc Institute
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arc Institute, Leland Stanford Junior University filed Critical Arc Institute
Publication of WO2024216211A2 publication Critical patent/WO2024216211A2/fr
Publication of WO2024216211A3 publication Critical patent/WO2024216211A3/fr
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/42—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving phosphatase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente divulgation concerne de manière générale des procédés d'inhibition et de prévention de métastases ainsi que des procédés de diagnostic d'un sujet comme présentant un risque de développer un cancer.
PCT/US2024/024497 2023-04-14 2024-04-12 Procédés d'inhibition de la progression d'une tumeur et de la métastase par inhibition de enpp1 Pending WO2024216211A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202363496281P 2023-04-14 2023-04-14
US63/496,281 2023-04-14
US202363505520P 2023-06-01 2023-06-01
US63/505,520 2023-06-01

Publications (2)

Publication Number Publication Date
WO2024216211A2 WO2024216211A2 (fr) 2024-10-17
WO2024216211A3 true WO2024216211A3 (fr) 2024-12-19

Family

ID=93060210

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/024497 Pending WO2024216211A2 (fr) 2023-04-14 2024-04-12 Procédés d'inhibition de la progression d'une tumeur et de la métastase par inhibition de enpp1

Country Status (1)

Country Link
WO (1) WO2024216211A2 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120009592A1 (en) * 2005-06-17 2012-01-12 Universite de Droit de la La Sante de Lille 2 Enpp1 (pc-1) gene haplotype associated with the risk of obesity and type 2 diabetes and their applications
WO2019177971A1 (fr) * 2018-03-12 2019-09-19 Mavupharma, Inc. Inhibiteurs d'ectonucléotide pyrophosphatase-phosphodiestérase 1 (enpp -1) et leurs utilisations
CN110244058B (zh) * 2019-06-10 2020-05-22 浙江大学 Enpp1在制备高级别浆液性卵巢癌诊断及预后试剂盒中的应用
US20210369747A1 (en) * 2017-09-08 2021-12-02 The Board Of Trustees Of The Leland Stanford Junior University ENPP1 Inhibitors and Their Use for the Treatment of Cancer
WO2022003152A2 (fr) * 2020-07-03 2022-01-06 Aarhus Universitet Compositions comprenant des vésicules extracellulaires et des agents stimulateurs de piqûre

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120009592A1 (en) * 2005-06-17 2012-01-12 Universite de Droit de la La Sante de Lille 2 Enpp1 (pc-1) gene haplotype associated with the risk of obesity and type 2 diabetes and their applications
US20210369747A1 (en) * 2017-09-08 2021-12-02 The Board Of Trustees Of The Leland Stanford Junior University ENPP1 Inhibitors and Their Use for the Treatment of Cancer
WO2019177971A1 (fr) * 2018-03-12 2019-09-19 Mavupharma, Inc. Inhibiteurs d'ectonucléotide pyrophosphatase-phosphodiestérase 1 (enpp -1) et leurs utilisations
CN110244058B (zh) * 2019-06-10 2020-05-22 浙江大学 Enpp1在制备高级别浆液性卵巢癌诊断及预后试剂盒中的应用
WO2022003152A2 (fr) * 2020-07-03 2022-01-06 Aarhus Universitet Compositions comprenant des vésicules extracellulaires et des agents stimulateurs de piqûre

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CAROZZA JACQUELINE A.; BROWN JENIFER A.; BöHNERT VOLKER; FERNANDEZ DANIEL; ALSAIF YASMEEN; MARDJUKI RACHEL E.; SMITH MARK; LI: "Structure-Aided Development of Small-Molecule Inhibitors of ENPP1, the Extracellular Phosphodiesterase of the Immunotransmitter cGAMP", CELL CHEMICAL BIOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 27, no. 11, 28 July 2020 (2020-07-28), AMSTERDAM, NL , pages 1347, XP086358979, ISSN: 2451-9456, DOI: 10.1016/j.chembiol.2020.07.007 *
CHOURABI MARWA, SAAD ALI, WONG PUI MUN: "New insights into the roles of SMB domains in the ENPP1 protein", RESEARCHGATE, 1 November 2017 (2017-11-01), XP093255310, Retrieved from the Internet <URL:https://www.researchgate.net/profile/Marwa-Chourabi/publication/324749920_New_insights_into_the_roles_of_SMB_domains_in_the_ENPP1_protein/links/5c04537ba6fdcc1b8d5096e8/New-insights-into-the-roles-of-SMB-domains-in-the-ENPP1-protein.pdf?origin=publication_detail&_tp=eyJjb250ZXh0Ijp7ImZpcnN0UGFnZSI6InB1YmxpY2F0aW9uIiwicGFnZSI6InB1YmxpY2F0aW9uRG93bmxvYWQiLCJwcmV2aW91c1BhZ2UiOiJwdWJsaWNhdGlvbiJ9fQ&__cf_chl_tk=MSuIuOieZg45f83mdMdVKkPh8DKMIO10IrcooLxN1nE-1740996672-1.0.1.1-HuLzkjA4Zqi86QeDcogqGvNzHgh8aqdlpcijjaY5w00> *
GHAFFARI ET AL.: "STING agonist therapy in combination with PD-1 immune checkpoint blockade enhances response to carboplatin chemotherapy in high-grade serous ovarian cancer", BRITISH JOURNAL OF CANCER, vol. 119, 26 July 2018 (2018-07-26), pages 440 - 449, XP036843791, Retrieved from the Internet <URL:https://www.nature.com/articles/s41416-018-0188-5> [retrieved on 20240709], DOI: 10.1038/s41416-018-0188-5 *
KAWAGUCHI MITSUYASU, HAN XIANG, HISADA TOMOKA, NISHIKAWA SAYAKA, KANO KUNIYUKI, IEDA NAOYA, AOKI JUNKEN, TOYAMA TATSUYA, NAKAGAWA : "Development of an ENPP1 Fluorescence Probe for Inhibitor Screening, Cellular Imaging, and Prognostic Assessment of Malignant Breast Cancer", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 62, no. 20, 24 October 2019 (2019-10-24), US , pages 9254 - 9269, XP093052058, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.9b01213 *

Also Published As

Publication number Publication date
WO2024216211A2 (fr) 2024-10-17

Similar Documents

Publication Publication Date Title
MX2023000025A (es) Inhibidores de la quinasa progenitora hematopoyética 1 y usos de estos.
PH12022551574A1 (en) Egfr inhibitors
WO2017053930A3 (fr) Méthode de traitement d&#39;une tumeur rhabdoïde maligne de l&#39;ovaire (mrto)/cancer à petites cellules de l&#39;ovaire du type hypercalcémique (sccoht) avec un inhibiteur d&#39;ezh2
GB1201132A (en) Scale inhibition
PH12019500957A1 (en) Selective inhibitor of exon 20 insertion mutant egfr
ZA202213152B (en) Novel acid secretion inhibitor and use thereof
WO2024216211A3 (fr) Procédés d&#39;inhibition de la progression d&#39;une tumeur et de la métastase par inhibition de enpp1
WO2023107574A3 (fr) Compositions à base de lipides et procédés associés
WO2020086595A8 (fr) Inhibition d&#39;usp7
CN115485282A (zh) 一种氧氮杂螺环化合物、其盐型及其晶型
WO2004110245A3 (fr) Polytherapie destinee au traitement du cancer
EP1335726A4 (fr) Formes modifiees du promedicament ap/amp
WO2021076817A3 (fr) Procédés et compositions associés au traitement et à la prévention du cancer par inhibition de dgat1 et dgat2
MY195435A (en) Anticancer Compounds
WO2020055544A3 (fr) Méthode de traitement du cancer du pancréas
WO2020176461A3 (fr) Méthodes et compositions pour le traitement du cancer neuroendocrinien de la prostate
WO2020251871A3 (fr) Nouveaux composés de tétrahydroquinoléine substitués en tant qu&#39;inhibiteurs de l&#39;indoléamine 2,3-dioxygénase (ido)
MY145842A (en) Method of producing triethanolamine
WO2003028642A3 (fr) Procede d&#39;inhibition de metastases
WO2019182746A3 (fr) Formulations de catalyseur
EA200001035A1 (ru) Способ ингибирования mrp1
WO2025190437A3 (fr) Dérivé d&#39;imidazobenzimidazole, son procédé de préparation et son utilisation
ATE406375T1 (de) Antitumor wirksame 2-substituierte d-homoestra-1, 3,5(10)-trien-3-yl sulfamate
EA202192088A1 (ru) Способ получения бензоазепинового соединения
WO2020214767A3 (fr) Composés et procédés pour imager l&#39;activité immune

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24789634

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE